|
業務類別
|
Biotechnology |
|
業務概覽
|
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development. |
| 公司地址
| 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 781 312-3013 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.jadebiosciences.com |
| 員工數量
| 55 |
| Mr. Bradford D. Dahms |
Principal Accounting Officer, Chief Financial Officer and Treasurer |
美元 233.01K |
28/04/2026 |
| Dr. Andrew James King, PhD |
President, Research and Development |
美元 507.30K |
28/04/2026 |
| Mr. Tom Frohlich |
Chief Executive Officer, President and Director |
美元 621.97K |
28/04/2026 |
| Ms. Elizabeth Balta, J.D. |
Chief Legal Officer and Corporate Secretary |
-- |
28/04/2026 |
|
|
| Mr. Eric L. Dobmeier, J.D. |
Chairman of the Board |
28/04/2026 |
| Ms. Erin M. Lavelle |
Independent Director |
28/04/2026 |
| Dr. Lawrence Otto Klein, PhD |
Independent Director |
28/04/2026 |
| Dr. Christopher Cain, PhD |
Independent Director |
28/04/2026 |
| Mr. Tomas Kiselak |
Independent Director |
28/04/2026 |
| Dr. Mark Eisner, M.D.,M.P.H. |
Director |
26/06/2026 |
| Mr. Tom Frohlich |
Chief Executive Officer, President and Director |
28/04/2026 |
|
|
|
|
